AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02737644 — intervention group
Intervention type: OTHER
Intervention: observation
Description: This is an observational study
Study NCT03226392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAW039
Description: QAW039 once daily
Study NCT03226392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT01604122 — intervention group
Intervention type: OTHER
Intervention: No drug
Description: No drug.
Study NCT02338531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Study NCT02338531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast cancer surgery
Study NCT02573727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nor adrenaline + albumin
Study NCT02573727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin + albumin
Study NCT03992157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG telemetry
Description: ECG telemetry (holter ECG) is a portable case - attached to the belt or around the neck - connected to 6 electrodes placed on the skin next to the heart. They are worn by patients during their stay in hospital
Study NCT01406431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin, Valsartan
Description: Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
Study NCT03984149 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Observational study: There is no intervention.
Study NCT01304368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thermotherapy
Description: Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
Study NCT01406431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livalo® fixed combination drug
Description: Livalo® fixed combination drug(1 tablet)
Study NCT04101981 — intervention group
Intervention type: PROCEDURE
Intervention: oocytes retrieval
Description: The oocytes retrieval was performed after 34-36 hours from hCG administration . The collection of cumulus-oocyte complexes and FFs were performed via transvaginal ultrasound-guided aspiration with a needle of 18 gauge of diameter. The three major diameter follicles were identified by intraoperative ultrasound and FF of each follicle was collected in its own test tube.
Study NCT02834533 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lokomat
Description: Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
Study NCT03241355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: prebiotic inulin-type fructan
Study NCT03241355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo maltodextrin
Study NCT03562104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: videofluoroscopy
Description: Swallowing description in Minimally consciousness Patient
Study NCT03281356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Participants will receive a total of 8 text messages during a 4 week period.
Study NCT03018340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
Study NCT03018340 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
Study NCT01550315 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsitile Arterial Tonometry (PAT) Protocol
Description: * A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).~* RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.~* Continuous recording of pulsatile blood volume responses from both hands will be initiated.~* After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped.
Study NCT01550315 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pulsitile Arterial Tonometry (PAT) Protocol
Description: * A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).~* RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.~* Continuous recording of pulsatile blood volume responses from both hands will be initiated.~* After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped.
Study NCT03562104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wessex Head Injury Matrix scale
Description: Wessex Head Injury Matrix scale in Minimally consciousness Patient
Study NCT01404845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrof Total
Description: Nutrof Total : 2 capsules per day,during 8 months (5 mg Lutéine + 1 mg Zéaxanthine / capsule).
Study NCT01404845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: food supplement without Lutein and Zeaxanthin
Description: food supplement without Lutein and Zeaxanthin : 2 capsules per day, during 8 months.
Study NCT03643094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Golden Black Seed
Description: 1 capsule per day for 8 weeks.
Study NCT01018368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: In Period 1, subjects will receive a single oral dose of VX-770 150 mg on Day 1. In Period 2, subjects will receive a single oral dose of VX-770 150 mg on Day 6.
Study NCT01018368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: In Period 2, subjects will receive a daily oral dose of rifampin 600 mg on Days 1 through 10
Study NCT02609048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Capsule (2 taken once daily)
Study NCT02609048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Seladelpar / MBX-8025 50 mg
Description: MBX-8025 50 mg capsule (1 taken once daily)
Study NCT02609048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Seladelpar / MBX-8025 200 mg
Description: MBX-8025 100 mg capsules (2 taken once daily)
Study NCT04524559 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional physical therapy training
Description: The program focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms. The program was applied via certified physical therapists five days/week for 4 successive months. The intended goals of the treatment program were achieved through:~* Neurodevelopmental based training (NDT)~* Functional stretching exercises to preserve muscle and soft tissues elasticity~* Sequenced trunk co-activation (STA) exercises~* Righting and protective reactions It is worth mentioned that the exercises applied in each session was influenced by the age and the specific functional abilities within the selected activity.
Study NCT04524559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy training
Description: The program focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms. The program was applied via certified physical therapists five days/week for 4 successive months. The intended goals of the treatment program were achieved through:~* Neurodevelopmental based training (NDT)~* Functional stretching exercises to preserve muscle and soft tissues elasticity~* Sequenced trunk co-activation (STA) exercises~* Righting and protective reactions It is worth mentioned that the exercises applied in each session was influenced by the age and the specific functional abilities within the selected activity.
Study NCT04524559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral motor training.
Description: Children in the experimental group received 30 minutes of oral motor training five days week. The training included oral stimulation (facilitation) conducted before the child's actual meal time.~The designed protocol comprised modified perioral and intraoral maneuvers based on Fucile's protocol. The utmost aims of the protocol were to decrease hypersensitivity of oral structures, increase jaws movement, and reinforce muscle strength, improve tongue movement and enhance oral motor organization
Study NCT00167102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
Study NCT00167102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alefacept
Description: Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
Study NCT00609791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: 100 mg/m2 3 weeks on 1 week off
Study NCT00609791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
Study NCT00609791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiologic testing
Description: Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
Study NCT00609791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
Study NCT00609791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study of socioeconomic and demographic variables
Description: Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
Study NCT00609791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive assessment
Description: Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
Study NCT00609791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Description: Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
Study NCT00159913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: oral; 20mg, 40mg and 80 mg; 3 times a day(TID)
Study NCT00159913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: oral; 10mg, 20mg and 40mg; 3 times a day(TID)
Study NCT00159913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral; 3 times a day(TID)
Study NCT00159913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: oral; 10 mg; 3 times a day(TID)
Study NCT04453813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab plus concurrent chemo-radiotherapy
Description: 1. Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of toripalimab are concurrently used during radiotherapy and other 9 cycles of toripalimab are used after the end of radiotherapy. (A total of 11 cycles).~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy
Study NCT04453813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemo-radiotherapy
Description: 1. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~2. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy
Study NCT00685646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiandrogen therapy
Description: Up to 24 courses of therapy
Study NCT00685646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antiandrogen therapy
Description: Up to 24 courses of therapy
Study NCT00685646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Up to 24 courses of therapy
Study NCT01338610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESBA105 ophthalmic solution
Study NCT01338610 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ESBA105 vehicle
Description: Inactive ingredients used as Run-In and placebo comparator
Study NCT03679299 — intervention group
Intervention type: OTHER
Intervention: Observational - No intervention
Description: See outcomes
Study NCT01550315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Calf Blood Flow in Reactive Hyperemia (CBF-RH)
Description: Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (\~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed
Study NCT01550315 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Calf Blood Flow in Reactive Hyperemia (CBF-RH)
Description: Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (\~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed
Study NCT01550315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of Forearm-Mediated Dilation
Description: The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
Study NCT01550315 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Evaluation of Forearm-Mediated Dilation
Description: The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
Study NCT01445002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM32
Description: Subcutaneous injection of 10 micrograms each of the BM32 components adsorbed on 0.3 mg of aluminum hydroxide every 4 week for a total of 3 injections
Study NCT01445002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM32
Description: Subcutaneous injection of 20 micrograms of each of the BM32 components adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections
Study NCT01445002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM32
Description: Subcutaneous injection of 40 micrograms of each of the BM32 components adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks until a total of 3 injections
Study NCT01445002 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every 4 weeks until 3 injections
Study NCT01836549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imetelstat sodium
Description: Given IV
Study NCT01377038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phenotype assessment
Description: Quantitative sensory testing and patient reported outcome measures used to assess patient pain phenotype
Study NCT04423887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy + Heating
Description: Interferential Current therapy (2P), in combination with heating pad for 20 minutes
Study NCT04423887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrotherapy + Heating
Description: Interferential Current therapy (2P), in combination with heating pad for 20 minutes
Study NCT04423887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Joint Mobilization
Description: Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
Study NCT04423887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
Study NCT04423887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Supplementation
Description: Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
Study NCT02308852 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Study NCT02308852 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Study NCT04938557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated closed-loop insulin delivery (AiD)
Description: Closed-loop systems are designed to deliver insulin in response to CGM glucose levels and may help to improve glucose control above and beyond what is currently achievable using insulin pumps, injections and CGM without AiD.
Study NCT04938557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A standard insulin delivery system
Description: Self-directed insulin delivery for pregnant women with T1D, which is insulin pump or MDI.
Study NCT03892590 — intervention group
Intervention type: BIOLOGICAL
Intervention: Gut microbiota
Description: Status of microbiota
Study NCT01166724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Tacrolimus to Sirolimus
Study NCT01166724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: dosage per trough level
Study NCT00965588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB 311
Description: Single liquid dose by intramuscular route at weeks 0, 4, 12.
Study NCT03927664 — intervention group
Intervention type: OTHER
Intervention: Radiological assessment
Description: Radiological assessment of findings in the peritoneum, omentum, mesentery, ascites and other abdominal findings
Study NCT00909116 — intervention group
Intervention type: PROCEDURE
Intervention: Stapled Transanal Rectal Resection with Contour Transtar
Description: Transanal Stapling procedure - Stapled Transanal Rectal Resection
Study NCT04364607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Participants will receive 0.5 mg IM neostigmine
Study NCT01396629 — intervention group
Intervention type: PROCEDURE
Intervention: cartridge
Description: IOL cartridge coated with polymer material may ensure smooth delivery of IOL during cataract surgery
Study NCT04364607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: Participants will receive IM NaCl 0.9% as a placebo
Study NCT03303079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125
Description: TEV-48125 will be subcutaneously administered once monthly for 3 months.